People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| XORTX Therapeutics Inc. | — | Pharma | Seed | $2.3M | $7.2M | 2024 |
Paul J. Van Damme at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul J. Van Damme on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Farley | 1 | 4 |
| Anthony J. Giovinazzo | 1 | 3 |
| Alan Moore | 1 | 3 |
| John Meekison | 1 | 3 |
| James Fairbairn | 1 | 2 |
| Raymond J. Pratt | 1 | 1 |
| Patrick J. Treanor | 1 | 1 |
| Bruce Rowlands | 1 | 1 |
| Allen Davidoff | 1 | 1 |
| Abigail J. Jenkins | 1 | 1 |
| Stephen Haworth | 1 | 1 |
| Stacy Evans | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.